Day: May 27, 2025

Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

Written by Customer Service on May 27, 2025. Posted in Public Companies.

NEEDHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Candel management will host a webcast and conference call on Tuesday, June 3, 2025, at 1:00PM ET. The call will discuss the Company’s positive phase 3 clinical results for CAN-2409 in localized, intermediate-to-high risk prostate cancer, which demonstrated a statistically significant 30% reduction in disease recurrence compared with placebo when combined with standard-of-care radiation therapy. The discussion will follow Dr. Theodore DeWeese’s* oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The call will also feature insights...

StepStone Group to Present at the Morgan Stanley US Financials Conference

Written by Customer Service on May 27, 2025. Posted in Public Companies.

NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) — StepStone Group Inc. (Nasdaq: STEP) today announced that Scott Hart, CEO, and Mike McCabe, Head of Strategy, are scheduled to present at the Morgan Stanley US Financials Conference on Tuesday, June 10, 2025, at 2:30 pm ET. A live webcast and replay will be accessible through the StepStone website at https://shareholders.stepstonegroup.com. About StepStone StepStone Group Inc. (Nasdaq: STEP) is a global private markets investment firm focused on providing customized investment solutions and advisory and data services to its clients. As of March 31, 2025, StepStone was responsible for approximately $709 billion of total capital, including $189 billion of assets under management. StepStone’s clients include some of the world’s largest public and private defined benefit and defined...

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June

Written by Customer Service on May 27, 2025. Posted in Public Companies.

NAARDEN, the Netherlands and MIAMI, May 27, 2025 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:William Blair 45th Annual Growth Stock Conference in Chicago, IL on Tuesday, June 3, 2025. Michael Davidson, M.D., Chief Executive Officer, will present a corporate overview at 3:20 p.m. CT on Tuesday, June 3. Jefferies Global Healthcare Conference 2025 in New York, NY on Wednesday, June 4, 2025. Ian...

Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

Written by Customer Service on May 27, 2025. Posted in Public Companies.

Novel combination with efti has met the trial’s primary endpoint of tumour hyalinization/fibrosis in the neoadjuvant setting for patients with resectable soft tissue sarcoma Detailed results are planned for presentation at a future medical meeting SYDNEY, AUSTRALIA, May 27, 2025 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces the investigator-initiated EFTISARC-NEO Phase II trial evaluating eftilagimod alfa (efti) with radiotherapy plus KEYTRUDA® (pembrolizumab) in the neoadjuvant setting for resectable soft tissue sarcoma (STS) has met its primary endpoint. The novel combination significantly exceeded the study’s prespecified median of 35% tumour hyalinization/fibrosis versus 15% for historical...

Check Point to Acquire Veriti to Transform Threat Exposure Management and Reduce Organizations’ Cyber Attack Surface

Written by Customer Service on May 27, 2025. Posted in Mergers And Acquisitions.

Veriti is the first to introduce preemptive exposure management delivering automated remediation of threat exposure risks and collaborative threat prevention across complex multi-vendor environments REDWOOD CITY, Calif., May 27, 2025 (GLOBE NEWSWIRE) — AI-fueled attacks and hyperconnected IT environments have made threat exposure one of the most urgent cybersecurity challenges facing enterprises today. In response, Check Point® Software Technologies Ltd. (NASDAQ: CHKP), a pioneer and global leader of cyber security solutions, today announced a definitive agreement to acquire Veriti Cybersecurity, the first fully automated, multi-vendor pre-emptive threat exposure and mitigation platform. “The acquisition of Veriti marks a significant step toward realizing our hybrid mesh security vision,” said Nadav Zafrir, CEO at Check Point Software...

Multi Ways Holdings Reports Financial Results for Fiscal Year 2024

Written by Customer Service on May 27, 2025. Posted in Earnings Releases And Operating Results.

SINGAPORE, May 27, 2025 (GLOBE NEWSWIRE) — Multi Ways Holdings Limited (“Multi Ways”, the “Company” or the “Issuer”) (NYSE American: MWG), a leading supplier of a wide range of heavy construction equipment for sales and rental in Singapore and the surrounding region, today announced fiscal year 2024 financial results. “We are pleased to report on the strategic advancements Multi Ways Holdings Limited has achieved over the past year,” said Mr. James Lim, Chairman and Chief Executive Officer of Multi Ways Holdings Limited. “Our ongoing fleet renewal and expansion initiatives are designed to meet the evolving requirements of our clients, ensuring they have access to the most advanced and dependable machinery available. With over two decades of industry experience, we have established ourselves as a reliable and trusted...

Evaxion announces business update and first quarter 2025 financial results

Written by Customer Service on May 27, 2025. Posted in Public Companies.

COPENHAGEN, Denmark, May 27, 2025 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces first quarter 2025 financial results. Business highlights (since last quarterly update)Evaxion has made good progress with continued execution of our strategy and plans. We have achieved the first two milestones for the year and are tracking towards future milestones and value catalysts. Highlights include:Continued progression of the development of our lead asset EVX-01 with the ongoing phase 2 trial on track for two-year readout in the second half of 2025, and the first patient in the one-year trial extension being dosed in May. Another set of positive data from the EVX-01 phase 2 trial presented at the AACR Annual...

Urgently Promotes Michael Port to Chief Financial Officer

Written by Customer Service on May 27, 2025. Posted in Public Companies.

VIENNA, Va., May 27, 2025 (GLOBE NEWSWIRE) — Urgent.ly Inc. (Nasdaq: ULY) (“Urgently”), a U.S.-based leading provider of digital roadside and mobility assistance technology and services, today announced the appointment of Michael Port as Chief Financial Officer, effective June 6, 2025. Mr. Port assumes the role from Timothy C. Huffmyer, who is stepping down as Chief Financial Officer to pursue other opportunities. Mr. Port previously served as Senior Vice President of Finance of Urgently. Prior to joining Urgently, Mr. Port served as Vice President of Finance and Controller of Lordstown Motors Corp. (“Lordstown”), an electric vehicle original equipment manufacturer and innovator, from September 2021 until June 2023, then Mr. Port consulted with Lordstown’s successor company, Nu Ride, Inc. (“Nu Ride”), providing transition services...

BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor

Written by Customer Service on May 27, 2025. Posted in Public Companies.

Bria-OTS has cleared its safety evaluation in the Phase 1/2 study monotherapy dosage setting Phase 1/2 study has now transitioned to dosing patients in combination with checkpoint inhibitor in metastatic breast cancer First Bria-OTS monotherapy patient remains on study with confirmed resolution of lung metastasisPHILADELPHIA and VANCOUVER, British Columbia, May 27, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ; TSX: BCT), a clinical-stage biotechnology company advancing personalized immunotherapies for cancer, today announced that Bria-OTS has cleared its safety evaluation in the Phase 1/2 monotherapy study and has now transitioned to dosing patients in combination with a checkpoint inhibitor (CPI). The first patient has been dosed in the checkpoint inhibitor combination cohort of the ongoing...

Purpose Investments Inc. Announces Final May 2025 Distribution Rate for Purpose High Interest Savings Fund, Purpose US Cash Fund, Purpose Cash Management Fund, and Purpose USD Cash Management Fund

Written by Customer Service on May 27, 2025. Posted in Dividend Reports And Estimates.

TORONTO, May 27, 2025 (GLOBE NEWSWIRE) — Purpose Investments Inc. announced today the final May 2025 distribution rates for Purpose High Interest Savings Fund, Purpose US Cash Fund, Purpose Cash Management Fund, and Purpose USD Cash Management Fund. The following table reflects the final distribution amounts for the month of May. Ex-distribution date is May 28, 2025.Open-End Fund Ticker Symbol Final distribution per unit Record Date Payable Date Distribution FrequencyPurpose USD Cash Management Fund – ETF Units MNU.U US $0.3531 05/28/2025 06/03/2025 MonthlyPurpose Cash Management Fund – ETF Units MNY $0.2373 05/28/2025 06/03/2025 MonthlyPurpose High Interest Savings Fund – ETF Units PSA $0.1070 05/28/2025 06/03/2025 MonthlyPurpose US Cash Fund – ETF Units PSU.U US $0.3495 05/28/2025 06/03/2025 Monthly About...

Day: May 27, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals